A61K

Drug Preparations & Formulations

USPTO Patent Applications

← All categories

335 items

Application

Methods And Systems For Predicting A Disease State Based On Analyzing Cfdna Fragments

US20260080975A1 · Foundation Medicine, Inc. · Mar 19, 2026
G16B A61K
Application

Systems And Methods For Classifying And Treating Homologous Repair Deficiency Cancers

US20260080973A1 · Foundation Medicine, Inc. · Mar 19, 2026
G16B A61K
Application

Cd127 Expression Inversely Correlates With Foxp3 And Suppressive Function Of Cd4+ Tregs

US20260079159A1 · Mar 19, 2026
G01N A61K
Application

Pyramidal Meditation Structure Device

US20260078593A1 · Mar 19, 2026
E04H A61K
Application

Methods Of Detecting Sjögren's Syndrome Using Salivary Exosomes

US20260078448A1 · Mar 19, 2026
C12Q A61K
Application

Multivalent Chlorotoxin Chimeric Antigen Receptors

US20260078529A1 · Mar 19, 2026
C40B A61K
Application

Polymer Nanoaggregate Pharmaceutical Composition And Use Thereof

US20260078219A1 · ANP Technologies, Inc. · Mar 19, 2026
C08G A61K
Application

Shaped Solid Particles Comprising Thermoplastic Copolymer, Production Method For Same, And Cosmetic Including Same

US20260078212A1 · Mar 19, 2026
C08F A61K
Application

A Solid Particle Of Organosilicon Functional Co Polymer, Manufacturing Process Thereof, And Cosmetics Comprising Said Solid Particle

US20260078211A1 · Mar 19, 2026
C08F A61K
Application

Carboxyalkyl Chitosan

US20260078203A1 · Mar 19, 2026
C08B A61K
Application

Orthogonal Mutations For Heterodimerization

US20260078202A1 · Mar 19, 2026
C07K A61K
Application

Anti Ptk7 Antibody, And Use Thereof

US20260078201A1 · Mar 19, 2026
C07K A61P
Application

Systems And Methods For Targeting Cancer Cells

US20260078200A1 · Mar 19, 2026
C07K A61K
Application

Methods And Materials For Assessing Response To Plasmablast And Plasma Cell Depleting Therapies

US20260078199A1 · Mar 19, 2026
C07K A61P
Application

Methods For Treating Cancer Using Subcutaneous Dosing Of Mosunetuzumab In Combination With Polatuzumab Vedotin

US20260078198A1 · Mar 19, 2026
C07K A61K
Application

Multispecific Constructs And Uses Thereof

US20260078196A1 · Mar 19, 2026
C07K A61P
Application

Multi Specific Antibody Binding To Bcma, Gprc5 D And Cd3, And Use Thereof

US20260078195A1 · Mar 19, 2026
C07K A61P
Application

Anti Tl1 A Antibody Therapeutic Methods

US20260078194A1 · Mar 19, 2026
C07K A61K
Application

Therapeutic Agents For Ocular Inflammatory Disease Comprising Interleukin 6 Receptor Inhibitor As Active Ingredient

US20260078193A1 · OSAKA UNIVERSITY · Mar 19, 2026
C07K A61K
Application

Combination Therapies With Bispecific Anti Egfr/C Met Antibodies And 3 Rd Generation Egfr Tyrosine Kinase Inhibitors

US20260078191A1 · Mar 19, 2026
C07K A61K
Application

Bispecific Tetravalent Antibodies And Methods Of Making And Using Thereof

US20260078190A1 · SystImmune, Inc. · Mar 19, 2026
C07K A61K
Application

Methods Of Treating Chronic Inflammatory Demyelinating Polyneuropathy Using Anti Fcrn Antibodies

US20260078189A1 · Immunovant Sciences GmbH · Mar 19, 2026
C07K A61K
Application

Methods Of Treating Cancer With An Anti Pd L1 Antibody

US20260078187A1 · Mar 19, 2026
C07K A61K
Application

Anti Pdl1 Antibody And Use Thereof

US20260078186A1 · Mar 19, 2026
C07K A61P
Application

Anti Vista Constructs And Uses Thereof

US20260078185A1 · Mar 19, 2026
C07K A61P
Application

Lag 3 Combination Therapy For The Treatment Of Cancer

US20260078184A1 · Bristol-Myers Squibb Company · Mar 19, 2026
C07K A61K
Application

Treating Chronic Inflammation And Cancer By Macrophage Polarization

US20260078183A1 · Mar 19, 2026
C07K A61K
Application

Therapeutic Agent For T Cell Malignancies

US20260078182A1 · MEIJI SEIKA PHARMA CO., LTD. · Mar 19, 2026
C07K A61K
Application

Anti Par2 Antibodies And Uses Thereof

US20260078180A1 · Mar 19, 2026
C07K A61P
Application

Cdh17 Antibodies And Uses Thereof

US20260078179A1 · Mar 19, 2026
C07K A61K
Application

Methods And Compositions For Increasing Iduronate 2 Sulfatase Activity In The Cns

US20260078178A1 · Mar 19, 2026
C07K C07K
Application

Connexin (Cx)43 Hemichannel Binding Antibodies And Uses Thereof

US20260078177A1 · Mar 19, 2026
C07K A61K
Application

Anti Abeta Antibodies

US20260078176A1 · Mar 19, 2026
C07K C07K
Application

Anti Sema3 A Antibodies And Their Uses For Treating A Thrombotic Disease Of The Retina

US20260078175A1 · Mar 19, 2026
C07K A61P
Application

Hcv Antigens And Antibodies

US20260078172A1 · Mar 19, 2026
C07K A61K
Application

Sars Cov2 Antibodies And Uses Thereof

US20260078171A1 · Mar 19, 2026
C07K A61P
Application

Pan Neutralizing Sars Co V 2 M Ab Composition And Methods Of Treatment Thereof

US20260078170A1 · Washington University · Mar 19, 2026
C07K A61K
Application

Hepatitis B Antibodies

US20260078169A1 · Mar 19, 2026
C07K A61K
Application

Fusion Protein

US20260078167A1 · Mar 19, 2026
C07K A61P
Application

Anti Dll3 Chimeric Antigen Receptors And Uses Thereof

US20260078166A1 · Mar 19, 2026
C07K A61K
Application

Processes For Generating Engineered Cells And Compositions Thereof

US20260078165A1 · Juno Therapeutics, Inc. · Mar 19, 2026
C07K A61K
Application

Compound, Preparation Method Thereof, And Lipid Nanoparticle And Pharmaceutical Composition

US20260078099A1 · SUZHOU HEALIRNA BIOTECHNOLOGY CO., LTD. · Mar 19, 2026
C07D A61K
Application

Piperazine Compounds

US20260078097A1 · Mar 19, 2026
C07D A61K
Application

Solid State Forms Of (S) 2 (((S) 6,8 Difluoro 1,2,3,4 Tetrahydronaphthalen 2 Yl)amino) N (1 (2 Methyl 1 (Neopentylamino)propan 2 Yl) 1 H Imidazol 4 Yl)pentanamide And Uses Thereof

US20260078096A1 · Mar 19, 2026
C07D A61K
Application

Neurotensin Receptor Ligands

US20260078095A1 · Mar 19, 2026
C07D A61K
Application

Anti Viral Compounds

US20260078094A1 · Mar 19, 2026
C07D A61K
Application

(4 R) 3 (4 Fluoro 2 Hydroxyphenyl) 4 Methyl 4,5 Dihydro 1 H Pyrazole 1 Carboximidamide Hydrochloride And Dermal Formulations Thereof

US20260078093A1 · IMMUNAHR AB · Mar 19, 2026
C07D A61K
Application

Sulfonyl Carboxamide Compound, Their Derivatives, And Uses Thereof

US20260078092A1 · Mar 19, 2026
C07D A61K
Application

Bioactive Phytochemicals In Zizyphus And Guarana

US20260078089A1 · Phytoquest Limited · Mar 19, 2026
C07D A23L
Application

Versatile Biodegradable Molecules As Nucleic Acid Carriers

US20260078086A1 · Mar 19, 2026
C07C A61K
Application

Ionizable Lipids For Nucleic Acid Delivery

US20260078085A1 · Mar 19, 2026
C07C A61K
Application

Compositions For Modulating Gut Microbiota

US20260078427A1 · Mar 19, 2026
C12Q A23L
Application

Differential Knockout Of An Allele Of A Heterozygous Elane Gene

US20260078415A1 · Mar 19, 2026
C12N A61K
Application

Materials And Methods For Treatment Of Pain Related Disorders

US20260078414A1 · Vertex Pharmaceuticals Incorporated · Mar 19, 2026
C12N A61K
Application

Methods And Products For Expressing Proteins In Cells

US20260078413A1 · Mar 19, 2026
C12N A61K
Application

Methods And Products For Transfecting Cells

US20260078409A1 · Mar 19, 2026
C12N A61K
Application

Muscle Specific Expression Cassettes

US20260078408A1 · Precision BioSciences, Inc. · Mar 19, 2026
C12N A61K
Application

Raav Vectors For The Treatment Of Gm1 And Gm2 Gangliosidosis

US20260078407A1 · Mar 19, 2026
C12N A61P
Application

Gene Therapy For Ceroid Lipofuscinoses

US20260078406A1 · Mar 19, 2026
C12N A61K
Application

Gene Therapy For Treating Citrullenemia

US20260078405A1 · The Trustees of the University of Pennsylvania · Mar 19, 2026
C12N A61P
Application

Zikv Based Gene Delivery System

US20260078403A1 · Mar 19, 2026
C12N A61K
Application

Scarless Genome Editing Through Two Step Homology Directed Repair

US20260078401A1 · The Board of Trustees of the Leland Stanford Junior University · Mar 19, 2026
C12N C12N
Application

Probiotics Designed To Express And Secrete Akkermansia Muciniphila Tars, And A Vector For Producing The Same

US20260078385A1 · Korea Research Institute of Bioscience and Biotechnolgy · Mar 19, 2026
C12N A61K
Application

G Quadruplex Containing Oligonucleotides

US20260078382A1 · Mar 19, 2026
C12N A61K
Application

Compounds And Compositions For Intracellular Delivery Of Therapeutic Agents

US20260078082A1 · Mar 19, 2026
C07C A61K
Application

Cationic Lipids And Uses Thereof

US20260078081A1 · Mar 19, 2026
C07C A61K
Application

Regulatable Cell Surface Receptors And Related Compositions And Methods

US20260078164A1 · Mar 19, 2026
C07K A61K
Application

T Cell Receptor That Targets Egfr Mutation And Methods Of Using The Same

US20260078163A1 · Mar 19, 2026
C07K A61K
Application

Reversible Control Of Chimeric Antigen Receptor T Cells

US20260078162A1 · Mar 19, 2026
C07K C07K
Application

Methods Of Using Activin Receptor Type Ii Variants

US20260078161A1 · Mar 19, 2026
C07K A61K
Application

Novel Pd1 Targeted Il 15 Immunocytokine And Vitokine Fusions

US20260078159A1 · Mar 19, 2026
C07K A61P
Application

Compositions Comprising Cxcl10 Derived Peptides And Methods Of Use Thereof

US20260078158A1 · University of Virginia Patent Foundation · Mar 19, 2026
C07K A01N
Application

Fgf21 Mutant Polypeptides

US20260078157A1 · Mar 19, 2026
C07K C07K
Application

Treatment Of Nervous System Injury And Neurodegenerative Disorders And Related Conditions

US20260078156A1 · Mar 19, 2026
C07K A61K
Application

Novel Folr1 Specific Binding Proteins For Cancer Diagnosis And Treatment

US20260078155A1 · Mar 19, 2026
C07K A61K
Application

System And Method For Redirecting Audio And Video Data Streams In A Display Server Computing System

US20260078154A1 · Netzyn, Inc. · Mar 19, 2026
C07K A61P
Application

Enzymatically Active Domains From Anti Staphylococcal Phage Proteins

US20260078152A1 · Mar 19, 2026
C07K A61K
Application

Novel Polypeptide

US20260078151A1 · Mar 19, 2026
C07K A61K
Application

Compositions And Methods For The Treatment Of Metabolic And Liver Disorders

US20260078149A1 · Mar 19, 2026
C07K A61P
Application

Amatoxin Antibody Drug Conjugates And Uses Thereof

US20260078148A1 · Heidelberg Pharma Research GmbH · Mar 19, 2026
C07K A61K
Application

Inhibitors For Protein N Terminal Methyltransferase And Uses Thereof

US20260078147A1 · Mar 19, 2026
C07K C07K
Application

Epha2 Targeting Agents And Uses Thereof

US20260078146A1 · The Regents of the University of California · Mar 19, 2026
C07K A61K
Application

Polypeptides Having Cholesterol Lowering Function In Soybean Protein Hydrolysate, Preparation Method Thereof, And Uses Thereof

US20260078145A1 · Mar 19, 2026
C07K A61P
Application

Active Peptide, And Composition And Use Thereof

US20260078144A1 · Mar 19, 2026
C07K A61K
Application

Compositions And Methods For Trehalose Phospholipids

US20260078140A1 · Mar 19, 2026
C07H A61K
Application

Compounds, Compositions, And Methods For Modulating Cftr

US20260078136A1 · Mar 19, 2026
C07F A61K
Application

Polycyclic Quinazolines For Inhibition Of Erbb2

US20260078135A1 · Mar 19, 2026
C07D A61K
Application

Macrocyclic Compounds As Ras Inhibitors

US20260078134A1 · BeOne Medicines I GmbH · Mar 19, 2026
C07D A61K
Application

Ras Inhibitors

US20260078133A1 · Mar 19, 2026
C07D A61K
Application

Nampt Modulators, Preparations, And Uses Thereof

US20260078130A1 · Mar 19, 2026
C07D A61K
Application

Bicyclic Urea Kinase Inhibitors And Uses Thereof

US20260078126A1 · THE BROAD INSTITUTE, INC. · Mar 19, 2026
C07D A61K
Application

Indazole Compounds As Pkmyt1 Kinase Inhibitors

US20260078122A1 · Hoffmann-La Roche Inc. · Mar 19, 2026
C07D A61K
Application

Inhibitors Of Enl/Af9 Yeats And Flt3

US20260078121A1 · Mar 19, 2026
C07D A61K
Application

Substituted Pyridopyrimidinones

US20260078120A1 · MIRATI THERAPEUTICS, INC. · Mar 19, 2026
C07D A61K
Application

Degrader Compounds And Uses Thereof

US20260078119A1 · Mar 19, 2026
C07D A61K
Application

Combined Product, Salt And Use Thereof

US20260078118A1 · Mar 19, 2026
C07D A61K
Application

Small Molecule Protein Synthesis Modulators

US20260078116A1 · Interdict Bio, Inc. · Mar 19, 2026
C07D A61K
Application

Compound Used As Inhibitor Of Cdk4 Kinase And Use Thereof

US20260078114A1 · Mar 19, 2026
C07D A61K
Application

Carbonic Anhydrase Enzyme Inhibitors And Methods Of Use Thereof

US20260078111A1 · RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Mar 19, 2026
C07D A61K
Application

Sesterterpenoid Compounds And Extract L01 Of Leucosceptrum Canum, And Use Thereof In Treatment Of Psoriasis

US20260078110A1 · Mar 19, 2026
C07D A61K
Application

Solid Forms Of A Rock Inhibitor

US20260078108A1 · Mar 19, 2026
C07D A61K
Application

Csf 1 R Inhibitors And Methods Of Use Thereof

US20260078107A1 · Mar 19, 2026
C07D A61K
Application

Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors

US20260078105A1 · Mar 19, 2026
C07D A61K
Application

Isoquinolones As Pi3 K Inhibitors

US20260078103A1 · OnKure, Inc. · Mar 19, 2026
C07D A61K
Application

Use Of A Janus Kinase Inhibitor And A Telomerase Inhibitor For The Treatment Of Myeloproliferative Neoplasms

US20260078379A1 · Mar 19, 2026
C12N A61K
Application

Construct Comprising Utr Sequence That Improves Intracellular Stability And Biosynthesis Of Mrna And Use Thereof

US20260078377A1 · THERAGEN BIO CO., LTD. · Mar 19, 2026
C12N A61K
Application

Oligonucleotides For The Treatment Of Breast Cancer

US20260078376A1 · Mar 19, 2026
C12N A61K
Application

Cyclic Antisense Therapeutics

US20260078373A1 · Mar 19, 2026
C12N A61K
Application

Method Of Inhibiting Durotaxis And/Or Treating Fibrosis

US20260078369A1 · Mar 19, 2026
C12N A61K
Application

Compositions And Methods For Treating Ornithine Transcarbamylase Deficiency

US20260078356A1 · Mar 19, 2026
C12N A61P
Application

Rna Programmable Epigenetic Rna Modifiers And Uses Thereof

US20260078355A1 · The Broad Institute, Inc. · Mar 19, 2026
C12N C12N
Application

Mammalian Cell Line For The Production Of Modified Vaccinia Virus Ankara (Mva)

US20260078353A1 · Bavarian Nordic A/S · Mar 19, 2026
C12N A61K
Application

Enhanced Adoptive Cell Therapy

US20260078349A1 · Mar 19, 2026
C12N A61K
Application

Clinical Derivations Of An Allogenic Cell And Therapeutic Uses

US20260078347A1 · Mar 19, 2026
C12N A61K
Application

Compositions For Promoting Activation Of Bone Marrow Derived Stem Cells Comprising Ccl5

US20260078344A1 · PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION · Mar 19, 2026
C12N A61K
Application

Modified Nk 92 Ha Nk003 Cells For The Clinic

US20260078342A1 · Mar 19, 2026
C12N A61K
Application

Treatment Of Cancer Using Chimeric Antigen Receptor

US20260078341A1 · Mar 19, 2026
C12N A61K
Application

Scaffolds With Stabilized Mhc Molecules For Immune Cell Manipulation

US20260078340A1 · Mar 19, 2026
C12N A61K
Application

Lactobacillus Acidophilus Goldgut La100 Having Functions Of Lipid Lowering, Blood Glucose Lowering And Weight Loss And Application Thereof

US20260078336A1 · Mar 19, 2026
C12N A61K
Application

A Method For Producing Heat Killed Lactic Acid Bacteria Which Have An Improved Activity Of Immune Regulation

US20260078334A1 · CJ CHEILJEDANG CORPORATION · Mar 19, 2026
C12N A61K
Application

Method Of Isolating Animal Gonadal Mesenchymal Stem Cells

US20260078333A1 · Mar 19, 2026
C12M A61K
Application

Nanoparticle Composition And Method Of Use And Manufacture

US20260078012A1 · Mar 19, 2026
C01G A61K
Application

Metered Dose Inhaler For Ipratropium Bromide Solution

US20260077140A1 · Mar 19, 2026
A61M A61K
Application

Spacer Device With Flow Rate Spirometer

US20260077139A1 · Aerovu Technologies, Inc. · Mar 19, 2026
A61M A61B
Application

Systems And Methods For Precision Dose Delivery, Sterlization, And Packaging Of Medical Devices

US20260077130A1 · Regeneron Pharmaceuticals, Inc. · Mar 19, 2026
A61M A61K
Application

Novel Enhanced Patch Pumps And Bihormonal Glucagon Patch Control Systems

US20260077127A1 · Beta Bionics, Inc. · Mar 19, 2026
A61M A61K
Application

Therapeutic Hydrogel Device

US20260077105A1 · Mar 19, 2026
A61L A61K
Application

Methods And Compositions For Imaging Malignancies In The Bone Marrow

US20260077072A1 · Mar 19, 2026
A61K A61P
Application

Targeted Delivery Of Theranostic Agents

US20260077071A1 · Mar 19, 2026
A61K C07B
Application

Method For Increasing Dispersion Stability Of Nanoparticles As T1 Mri Contrast Agent And T1 Mri Contrast Nanoparticles

US20260077070A1 · INVENTERA INC. · Mar 19, 2026
A61K A61K
Application

Combinations Of Contrast Agents

US20260077069A1 · Mar 19, 2026
A61K A61K
Application

Atp Independent Bioluminescent Reporter Variants To Improve In Vivo Imaging

US20260077068A1 · Mar 19, 2026
A61K C07D
Application

Imaging Compounds For Detecting Or Imaging Senescent Cells

US20260077067A1 · Mar 19, 2026
A61K A61K
Application

Receptor Targeting Conjugate With An Effective Pharmacokinetic Profile

US20260077066A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Assessing Kinase Activity

US20260077065A1 · Mar 19, 2026
A61K A61K
Application

Optimized Cln1 Genes And Expression Cassettes And Their Use

US20260077064A1 · Mar 19, 2026
A61K C12N
Application

Universal Non Viral Gene Delivery System With Enhanced Stability

US20260077063A1 · Mar 19, 2026
A61K A61K
Application

Antibody Gene Therapy For Treatment And Prevention Of Infection By Rabies Lyssavirus

US20260077062A1 · Auburn University · Mar 19, 2026
A61K A61P
Application

Compositions And Methods For In Vivo Nuclease Mediated Gene Targeting For The Treatment Of Genetic Disorders In Adult Patients

US20260077061A1 · The Trustees of the University of Pennsylvania · Mar 19, 2026
A61K A61K
Application

Methods Of Treating Or Preventing Amyotrophic Lateral Sclerosis

US20260077060A1 · Rowan University · Mar 19, 2026
A61K C12N
Application

Anti Ghrelin Butyrylcholinesterase Enzyme Therapeutic

US20260077059A1 · Mar 19, 2026
A61K A61K
Application

Peptide Type Nucleic Acid Carrier, Gene Therapeutic Composition Including It And Use Thereof

US20260077058A1 · Mar 19, 2026
A61K A61K
Application

Nucleic Acid Carrier And Method For Administering Nucleic Acid

US20260077057A1 · Mar 19, 2026
A61K A61K
Application

Linker Payload Compound, Conjugates And Applications Thereof

US20260077056A1 · Mar 19, 2026
A61K A61K
Application

Compositions Of Polyplexes And Saponins

US20260077055A1 · Mar 19, 2026
A61K A61K
Application

Combinations Of Anti Gip Antibodies And Incretins And Uses Thereof

US20260077054A1 · Mar 19, 2026
A61K A61K
Application

Combination Therapy For The Treatment Of Depression

US20260077192A1 · Mar 19, 2026
A61N A61K
Application

Combination Therapy For The Treatment Of Depression

US20260077191A1 · Mar 19, 2026
A61N A61K
Application

Antibodies And Enonomers

US20260077053A1 · Mar 19, 2026
A61K A61K
Application

Methods For Reducing Or Preventing Sars Cov 2 Infection And Transmission

US20260077052A1 · Mar 19, 2026
A61K A61K
Application

Compounds For The Degradation Of Egfr Kinase

US20260077051A1 · BeOne Medicines I GmbH · Mar 19, 2026
A61K A61K
Application

Protac Degraders Of Sars Cov 2 Main Protease

US20260077050A1 · Mar 19, 2026
A61K A61K
Application

Compounds Including A Mutant Kras Sequence And A Lipid And Uses Thereof

US20260077049A1 · Mar 19, 2026
A61K A61K
Application

Pharmaceutical Compositions Comprising Meloxicam

US20260077048A1 · Mar 19, 2026
A61K A61K
Application

Cancer Therapy

US20260077047A1 · TURBINE SIMULATED CELL TECHNOLOGIES LTD · Mar 19, 2026
A61K A61K
Application

Targeting The Pvr Axis Using Car T Cell Therapy And Combinations

US20260077046A1 · Mar 19, 2026
A61K A61K
Application

Method To Generate Improving Car T Cells

US20260077045A1 · Mar 19, 2026
A61K A61K
Application

Combination Therapy Employing A Pd1 Lag3 Bispecific Antibody And An Hla G T Cell Bispecific Antibody

US20260077044A1 · Hoffmann-La Roche Inc. · Mar 19, 2026
A61K A61P
Application

Combination Therapy

US20260077043A1 · Mar 19, 2026
A61K A61K
Application

Methods Of Treating Psoriatic Arthritis Using Il 17 Antagonists

US20260077042A1 · Mar 19, 2026
A61K A61K
Application

Bispecific Fusion Protein Targeting Tnf A And Il 17 A, And Use Thereof

US20260077041A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Treating Advanced Solid Tumors

US20260077040A1 · Mar 19, 2026
A61K A61K
Application

Anti Human Complement C5 Antibody And Fusion Protein Thereof

US20260077039A1 · Mar 19, 2026
A61K A61K
Application

Lipid Nanoparticles For Delivery Of Nucleic Acids And Methods Of Use Thereof

US20260077038A1 · Akagera Medicines, Inc. · Mar 19, 2026
A61K A61K
Application

Cationic Lipid Based Composition, Formulation And Use For Nucleic Acid Vaccine Delivery And Preparation Thereof

US20260077037A1 · BHARAT BIOTECH INTERNATIONAL LIMITED · Mar 19, 2026
A61K A61K
Application

Veterinary Product

US20260077036A1 · LETI Pharma, S.L. · Mar 19, 2026
A61K A61K
Application

Immunization Method Against Infection By Sars Co V 2

US20260077035A1 · Imam Abdulrahman Bin Faisal University · Mar 19, 2026
A61K A61K
Application

Multivalent Carriers And Related Vaccine Compositions

US20260077034A1 · Mar 19, 2026
A61K A61K
Application

Methods For Treating Or Preventing Respiratory Diseases In Cattle Using Polymers And Polyplexes For M Rna Delivery And M Rna Therapy

US20260077033A1 · MISSISSIPPI STATE UNIVERSITY OFFICE OF TECHNOLOGY MANAGEMENT · Mar 19, 2026
A61K A61P
Application

Kari Nanoparticle

US20260077032A1 · La Jolla Institute for Immunology · Mar 19, 2026
A61K A61K
Application

Nucleic Acids Encoding Human Endogenous Retrovirus K (Herv K) Envelope Proteins Containing Modified Immunosuppressive Domains (Isd) And Uses Thereof

US20260077031A1 · INPROTHER APS · Mar 19, 2026
A61K A61K
Application

Membrane Vesicles Comprising Multiple Influenza Antigens For Vaccines

US20260077030A1 · Mar 19, 2026
A61K A61P
Application

Immunogenic Compositions Of Pe Gylated Polysaccharide Compounds

US20260077029A1 · Inventprise, Inc. · Mar 19, 2026
A61K A61K
Application

Methods For Treating Netosis And Neutrophil Activation

US20260077028A1 · TRUSTEES OF BOSTON UNIVERSITY · Mar 19, 2026
A61K A61K
Application

Peptide And Nucleic Acid Methods To Modulate Delivery Of Nucleic Acid Structures, Polypeptides, And Their Cargoes

US20260077027A1 · Mar 19, 2026
A61K A61P
Application

Methods For Treating Cancer With Hyperactive Adar Enzymes

US20260077026A1 · THE UNIVERSITY OF CHICAGO · Mar 19, 2026
A61K A61K
Application

Sialylated Glycoprotein Composition And Uses Thereof

US20260077025A1 · Mar 19, 2026
A61K A61K
Application

Agent For Improving Intestinal Flora

US20260077024A1 · Mar 19, 2026
A61K A61K
Application

Antimicrobial Hydrolyzed Collagen With Polylysine And Methods Of Using The Same

US20260077023A1 · Rochal Technologies, LLC · Mar 19, 2026
A61K A61K
Application

Core Four Dietary Supplement System

US20260077022A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Treating Endocrine Diseases And Disorders

US20260077021A1 · Mar 19, 2026
A61K A61K
Application

Oral Peptide Pharmaceutical Composition That Facilitates Enhanced Oral Absorption

US20260077020A1 · Mar 19, 2026
A61K A61K
Application

Trizepatide And Other Glp1 Ra As A Novel Treatment For Patients With Lipodystrophy

US20260077019A1 · Rutgers, The State University of New Jersey · Mar 19, 2026
A61K A61K
Application

Treatment Of Mild Traumatic Brain Injury

US20260077018A1 · Mar 19, 2026
A61K A61P
Application

Adrenomedullin Analogs And Methods Of Use Thereof

US20260077017A1 · Mar 19, 2026
A61K A61P
Application

Novel Composition Comprising Antibodies

US20260077016A1 · Mar 19, 2026
A61K A61K
Application

Cellular Immunotherapy Compositions And Uses Thereof

US20260077015A1 · Mar 19, 2026
A61K A61K
Application

Covalent Dual Functional Inhibitors Of Peanut Allergies

US20260077014A1 · Mar 19, 2026
A61K A61K
Application

Combinations For Use In Cancer Therapy

US20260077013A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Diagnosis And Treatment Of Neurodegenerative Diseases

US20260077012A1 · Mar 19, 2026
A61K A61K
Application

Integrin Inhibitors As Therapy For Obesity Disorders

US20260077011A1 · Mar 19, 2026
A61K A61P
Application

Complex With Stroke Therapeutic Characteristic, And Preparation Method And Use Thereof

US20260077010A1 · Beijing Technology and Business University · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Treating Neurological Disorders

US20260077009A1 · Neurotech International Ltd · Mar 19, 2026
A61K A61K
Application

Composition For Promoting Cognitive Functions And Methods Of Making And Using The Same

US20260077008A1 · Mar 19, 2026
A61K A61K
Application

Novel Component For Controlling Biological Function

US20260077007A1 · Mar 19, 2026
A61K A61K
Application

Oncolytic Virus Expressing An Immune Cell Engager For Tumor Targeting

US20260077006A1 · Mar 19, 2026
A61K A61P
Application

Lentiviral Vector Formulations

US20260077005A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Treatment Of Cardiac Disorders

US20260077004A1 · University of Massachusetts · Mar 19, 2026
A61K A61K
Application

Lactobacillus Reuteri And Use, Composition, Drug And Food Thereof

US20260077003A1 · WISBIOM (BEIJING) Biotechnology Co., Ltd. · Mar 19, 2026
A61K A23C
Application

Probiotic Compositions And Methods

US20260077002A1 · UNIVERSITY OF OTTAWA · Mar 19, 2026
A61K A61K
Application

Bacterial Compositions And Methods Of Use

US20260077001A1 · Mar 19, 2026
A61K A61K
Application

Metabolic Modulation Of Intratumoral Cholesterol With Engineered Bacteria For The Treatment Of Cancers

US20260077000A1 · Mar 19, 2026
A61K A61K
Application

Preservation Of Pancreatic Islet Grafts In The Extrahepatic Space

US20260076999A1 · Mar 19, 2026
A61K A61K
Application

Method For Obtaining An Umbilical Cord Extract

US20260076998A1 · THE UNIVERSIDAD SAN FRANCISCO DE QUITO USFQ · Mar 19, 2026
A61K A61P
Application

Cell Implant Including Biodegradable Porous Microwell With Stem Cell Derived Insulin Secreting Cell Aggregate Supported Therein, And Use Thereof

US20260076997A1 · Mar 19, 2026
A61K A61P
Application

Composition For Treating Spinal Cord Injury, Comprising Stem Cells Treated With Novel Compound

US20260076996A1 · YJ CERAPEUTICS INC. · Mar 19, 2026
A61K A61P
Application

Bispecific Chimeric Antigen Receptors Targeting Cd20 And Bcma

US20260076995A1 · ABELZETA INC. · Mar 19, 2026
A61K A61K
Application

Photosynthetic Cellular Substances And Methods Of Use Thereof

US20260076994A1 · Mar 19, 2026
A61K A61N
Application

Composition For The Treatment Of Lesions Of The Respiratory System

US20260076993A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Treating Vaginal Atrophy

US20260076992A1 · Mar 19, 2026
A61K A61K
Application

Hyaluronic Acid Nanoparticles Comprising Nadph Oxidases Inhibitors And Uses In Treating Cancer

US20260076991A1 · Mar 19, 2026
A61K A61K
Application

Dsrna, Use Thereof And Preparation Method Therefor

US20260076990A1 · Mar 19, 2026
A61K A61K
Application

Hyaluronic Acid Collagen Matrices For Dermal Filling And Volumizing Applications

US20260077100A1 · Mar 19, 2026
A61L A61K
Application

Agents For Cleaving Labels From Biomolecules In Vivo

US20260077076A1 · Tagworks Pharmaceuticals B.V. · Mar 19, 2026
A61K A61K
Application

Radiopharmaceutical Compositions For Actinium In Targeted Radionuclide Therapy

US20260077075A1 · Mar 19, 2026
A61K A61K
Application

Radiopharmaceutical Compositions For Actinium In Targeted Radionuclide Therapy

US20260077074A1 · Mar 19, 2026
A61K A61K
Application

Gastrin Releasing Peptide Receptor (Grpr) Targeted Compounds And Uses Thereof

US20260077073A1 · Mar 19, 2026
A61K A61K
Application

Color Changing Denture Mold

US20260076786A1 · Mar 19, 2026
A61C A61K
Application

Virus Like Particles For Preventing The Spreading And Lowering The Infection Rate Of Viruses

US20260076920A1 · Mar 19, 2026
A61K A61K
Application

Layer By Layer Delivery Of Active Agents

US20260076919A1 · Mar 19, 2026
A61K A61K
Application

Heterotelechelic Compounds

US20260076918A1 · KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION · Mar 19, 2026
A61K A61K
Application

Composition And Process For A Lipid Nano Particle Delivery Of Oxygen And Vital Metabolic Compounds For Hemorrhagic Shock

US20260076917A1 · Mar 19, 2026
A61K A61K
Application

Methylphenidate Modified Release Formulations

US20260076916A1 · Mar 19, 2026
A61K A61K
Application

Modified Release Formulation Comprising Capsaicinoids And A Process

US20260076915A1 · Mar 19, 2026
A61K A23L
Application

Ionizable Lipids And Compositions Comprising Same

US20260076914A1 · Mar 19, 2026
A61K C07C
Application

Stabilized Microcapsules, Method Of Their Preparation And Uses Thereof

US20260076913A1 · Mayne Pharma LLC · Mar 19, 2026
A61K A61K
Application

Pharmaceutical Compositions And Methods

US20260076912A1 · Mar 19, 2026
A61K A61K
Application

Particles, Method For Producing Particles, And Pharmaceutical Composition

US20260076911A1 · ETRIA Co., Ltd. · Mar 19, 2026
A61K A61K
Application

Use Of Higher Doses Of Modified Release Huperzine Formulations

US20260076910A1 · Biscayne Neurotherapeutics, Inc. · Mar 19, 2026
A61K A61K
Application

Solid Composition And Method For Producing The Same

US20260076909A1 · DKS Co. Ltd. · Mar 19, 2026
A61K A61K
Application

Plurality Of Tasquinimod Particles And Use Thereof

US20260076908A1 · ACTIVE BIOTECH AB · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Compartment Specific Cargo Delivery

US20260076907A1 · Mar 19, 2026
A61K A61K
Application

Nanoparticles For Enhancing Mitochondrial Networks

US20260076906A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods Comprising Lipid Nanoparticle Vaccines That Elicit A Modulated Immune Response

US20260076905A1 · Mar 19, 2026
A61K A61K
Application

Nano Particles Of Menaquinone 9 And Methods Of Treatment

US20260076904A1 · Mar 19, 2026
A61K A61K
Application

Formulations Of Anti Interleukin 1 Receptor 1 Antibodies

US20260076903A1 · Mar 19, 2026
A61K A61K
Application

Liquid, Storage Stable, Directly Injectable, Pantoprazole Formulations, Their Uses And Manufacturing

US20260076902A1 · Mar 19, 2026
A61K A61K
Application

Material For Gel Formation And Gel Composition

US20260076901A1 · Kewpie Corporation · Mar 19, 2026
A61K A61K
Application

Ipratropium Delivery Compositions, Devices And Methods

US20260076900A1 · Solstice Advanced Materials US, Inc. · Mar 19, 2026
A61K A61K
Application

Targeted Release Rifaximin Compositions

US20260076899A1 · Bausch Health Ireland Limited · Mar 19, 2026
A61K A61K
Application

Method For Treating X Linked Retinoschisis (Xlrs) And/Or For Reducing Intraretinal Cysts In A Subject

US20260076898A1 · Mar 19, 2026
A61K A61K
Application

Dry Powder Formulations Of Epinephrine And Associated Methods

US20260076897A1 · Belhaven BioPharma Inc. · Mar 19, 2026
A61K A61K
Application

Continuous Or Periodical Transdermal Delivery Of Exogenous Molecule

US20260076896A1 · Mar 19, 2026
A61K A61K
Application

Device For Providing A Beverage Additive

US20260076895A1 · Mar 19, 2026
A61K A23L
Application

Oral Care Compositions Comprising Hops And Tin

US20260076894A1 · Mar 19, 2026
A61K A61K
Application

Self Foaming Cleansing Composition

US20260076893A1 · Conopco, Inc., d/b/a UNILEVER · Mar 19, 2026
A61K A61K
Application

Gel Composition And Oil In Water Composition

US20260076892A1 · Shiseido Company, Ltd. · Mar 19, 2026
A61K A61K
Application

Polyorganosiloxane Emulsions With Large Particle Size And Process For Their Preparation

US20260076891A1 · Wacker Chemie AG · Mar 19, 2026
A61K A61K
Application

Aqueous Personal Care Rinse Off Composition

US20260076890A1 · Mar 19, 2026
A61K A61K
Application

Polyester Film Forming Polymers For Alcoholbased Sunscreen Formulations

US20260076889A1 · NOURYON CHEMICALS INTERNATIONAL B.V. · Mar 19, 2026
A61K A61K
Application

Skincare Compositions For Controlled Delivery Of Active Agents

US20260076888A1 · Mar 19, 2026
A61K A61K
Application

Personal Care Compositions Containing Tailored Monolipid Rhamnolipids And Sulfate Free Surfactants

US20260076887A1 · Mar 19, 2026
A61K A61K
Application

Methods And Compositions For Skin Improvements

US20260076886A1 · NEWMEDICAL TECHNOLOGY, INC. · Mar 19, 2026
A61K A61K
Application

Complexation Of Oxybenzone With C Methylresorcin[4]Arene

US20260076885A1 · University of Cincinnati · Mar 19, 2026
A61K A61K
Application

Dry Shampoo And Related Methods

US20260076884A1 · Mar 19, 2026
A61K A61K
Application

Dry Shampoo And Related Methods

US20260076883A1 · Mar 19, 2026
A61K A61K
Application

Phosphate Crosslinked Starch Nanoparticle And Dental Treatments

US20260076882A1 · Mar 19, 2026
A61K A61K
Application

Aragonite Compositions, Methods, And Uses Thereof

US20260076881A1 · Nant Holdings IP, LLC · Mar 19, 2026
A61K A61K
Application

Hair Treatment Formulations, Dispensing Devices, And Methods

US20260076880A1 · Mar 19, 2026
A61K A45D
Application

Aluminum Free, Fatty Acid Coated Inorganic Powder And Method For Preparing Same

US20260076879A1 · Mar 19, 2026
A61K A61K
Application

Oral Liquid Dental Suspension Forming A Varnish For Controlled Teeth Whitening And Enamel Care

US20260076878A1 · Mar 19, 2026
A61K A61K
Application

System And Method For Rapid Assessment Of Renal Function

US20260076602A1 · Mar 19, 2026
A61B A61B
Application

Oligonucleotides, Compositions And Methods Thereof

US20260076989A1 · Mar 19, 2026
A61K A61K
Application

Timed Alternate Administration Of Decitabine And 5 Azacytidine For Cancer Treatment

US20260076988A1 · Mar 19, 2026
A61K A61K
Application

Injectable Hydrogel For Pet Endometritis, And Preparation Method And Use Thereof

US20260076987A1 · Mar 19, 2026
A61K A61K
Application

A Combination Of Scyllo Inositol And Flavones

US20260076986A1 · Mar 19, 2026
A61K A61K
Application

Long Acting Liposomal Composition For Treatment Of Pain In Articular Disorders

US20260076985A1 · MOEBIUS MEDICAL LTD. · Mar 19, 2026
A61K A61K
Application

Treatment Of Blood Loss At Tissue Wound

US20260076676A1 · Mar 19, 2026
A61B A61B
Application

Imaging Of Brain Lesions

US20260076634A1 · Blue Earth Diagnostics Limited · Mar 19, 2026
A61B A61B
Application

Treatment Of Behavioral Impairment In Developmental And Epileptic Encephalopathy

US20260076984A1 · Harmony Biosciences Management, Inc. · Mar 19, 2026
A61K A61M
Application

Cannabinoids Compositions With Polyunsaturated Fatty Acid Monoglycerides As A Specific Cox 2 Inhibitor, Methods And Uses Thereof

US20260076983A1 · SCF PHARMA INC. · Mar 19, 2026
A61K A61K
Application

Prodrugs Of Cannbidiol [Cbd] Type Phytocannabinoids And A Process For Preparation Thereof

US20260076982A1 · Mar 19, 2026
A61K A61K
Application

Hair Regrowth Topical Composition

US20260076981A1 · Mar 19, 2026
A61K A61K
Application

Composition For The Treatment Of Covid 19

US20260076980A1 · Mar 19, 2026
A61K A61K
Application

Composition For The Treatment Of Covid 19

US20260076979A1 · Mar 19, 2026
A61K A61K
Application

Compositions For Non Surgical Prevention Of Boar Taint And Aggressive Behavior

US20260076978A1 · Mar 19, 2026
A61K A61K
Application

Methods For Treatment Of Diseases

US20260076977A1 · Mar 19, 2026
A61K A61K
Application

Treatment For Heart Failure With Preserved Ejection Fraction With Guanethidine And Guanadrel

US20260076976A1 · Mar 19, 2026
A61K A61K
Application

Tpk Agonist And Method For Using Same To Treat Neurodegenerative Diseases

US20260076975A1 · Mar 19, 2026
A61K A61K
Application

Compositions For Preventing And Treating Infection Comprising An Artificial Sweetener

US20260076974A1 · Brunel University London · Mar 19, 2026
A61K A61K
Application

Compounds And Methods For Treating Diseases Caused By Sars Co V 2 And Other Coronaviruses

US20260076973A1 · Viradem, Inc. · Mar 19, 2026
A61K A61P
Application

Antidiabetic Medications

US20260076972A1 · Mar 19, 2026
A61K A61K
Application

Methods Of Treating Epilepsy And Reducing The Incidence Of Seizures

US20260076971A1 · Wisconsin Alumni Research Foundation · Mar 19, 2026
A61K A61K
Application

Cancer Treatment Using Mtdp Inhibitors And Plk1 Inhibitors

US20260076970A1 · Mar 19, 2026
A61K A61K
Application

Methods And Compositions For The Treatment Of Cancer

US20260076969A1 · Board of Regents, The University of Texas System · Mar 19, 2026
A61K A61K
Application

Aza Quinoline Compounds And Uses Thereof

US20260076968A1 · Mar 19, 2026
A61K A61K
Application

Heterocyclic Derivatives, Pharmaceutical Compositions And Their Use In The Treatment Or Amelioration Of Cancer

US20260076967A1 · Tolremo Therapeutics AG · Mar 19, 2026
A61K A61K
Application

Method Of Inhibiting Trem 1

US20260076966A1 · University of Florida Research Foundation, Incorporated · Mar 19, 2026
A61K A61P
Application

Method Of Treating Sclc And Managing Thrombocytopenia

US20260076965A1 · Mar 19, 2026
A61K A61K
Application

Method Of Treating Sclc And Managing Hepatotoxicity

US20260076964A1 · Mar 19, 2026
A61K A61K
Application

Methods Of Treating Heart Failure With Preserved Ejection Fraction Using Modified Forms Of Trimetazidine

US20260076963A1 · Mar 19, 2026
A61K A61K
Application

Lanthionine Synthetase C Like 2 Based Therapeutics

US20260076962A1 · NImmune Biopharma, Inc. · Mar 19, 2026
A61K A61K
Application

Combination Treatments

US20260076961A1 · Celex Oncology Innovations Limited · Mar 19, 2026
A61K A61K
Application

Metap2 Inhibitors And Methods Of Treating Obesity

US20260076960A1 · Mar 19, 2026
A61K A61K
Application

Combination Product, Salt, And Use Thereof In Treating Neurodegenerative Diseases Or Disorders

US20260076959A1 · Mar 19, 2026
A61K A61K
Application

Liquid Formulations Of Indacaterol

US20260076958A1 · Mar 19, 2026
A61K A61K
Application

Nicotine Based Gum Formulation

US20260076957A1 · Mar 19, 2026
A61K A23G
Application

Methods For Regressing Or Reversing Fibrosis And/Or Liver Cirrhosis In A Subject In Need Thereof Using High Dose Niacin, Or A Niacin Analog Thereof

US20260076956A1 · Mar 19, 2026
A61K A61K
Application

Joint Cavity Drug Administration Method, And Use Thereof

US20260076955A1 · TENNOR THERAPEUTICS (SUZHOU) LIMITED · Mar 19, 2026
A61K A61P
Application

Compositions And Methods For Reducing Cancer Stem Cells

US20260076954A1 · The Regents of the University of Colorado, A Body Corporate · Mar 19, 2026
A61K A61K
Application

Methods Of Diagnosing And Treating Adhd In Biomarker Positive Subjects

US20260076953A1 · The Children's Hospital of Philadelphia · Mar 19, 2026
A61K A61K
Application

Agent For Treatment Of Neutropenia

US20260076952A1 · Mar 19, 2026
A61K A61K
Application

Methods Of Treating Fabry Disease In Patients Having Renal Impairment

US20260076951A1 · Amicus Therapeutics, Inc. · Mar 19, 2026
A61K A61P
Application

Use Of A Phosphodiesterase 10 Inhibitor For The Treatment Of Tourette Syndrome

US20260076950A1 · Mar 19, 2026
A61K A61K
Application

Stable Monohydrate Of Df2755 A And Process For Its Preparation

US20260076949A1 · Mar 19, 2026
A61K C07D
Application

Treatment Of Diabetic Retinopathy Using Endothelin Receptor Antagonists

US20260076948A1 · Mar 19, 2026
A61K A61K
Application

Agents That Target Telomerase Reverse Transcriptase (Tert) For Treating Cancer And Sensitizing Cancer Cells To Genotoxic Therapy

US20260076947A1 · Mar 19, 2026
A61K A61K
Application

Viral Inhibitors, The Synthesis Thereof, And Intermediates Thereto

US20260076946A1 · Mar 19, 2026
A61K A61K
Application

Viral Inhibitors, The Synthesis Thereof, And Intermediates Thereto

US20260076945A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods For Promoting Brain Health

US20260076944A1 · Mar 19, 2026
A61K A61K
Application

Method For Improving Skeletal Health

US20260076943A1 · Mar 19, 2026
A61K A61P
Application

Aryl Imino Tryptophan Derivatives

US20260076942A1 · Renovel Innovations, Inc. · Mar 19, 2026
A61K A61P
Application

Indolinone Compounds And Uses Thereof

US20260076941A1 · Mar 19, 2026
A61K A61K
Application

Treatment Regimen For The Treatment Of Neurological Diseases Or Conditions

US20260076940A1 · Accure Therapeutics, S.L. · Mar 19, 2026
A61K A61K
Application

Chiral Gamma Lactam Derivative Or Pharmaceutically Acceptable Salt Thereof, And Preparation Method Therefor

US20260076939A1 · Mar 19, 2026
A61K A61P
Application

Methods And Compositions For Treating Male Sexual Disorders And Improving Sexual Function

US20260076938A1 · GTO Pharma, LLC · Mar 19, 2026
A61K A61K
Application

Composition For Preventing Or Treating Autoimmune Diseases Comprising A Bcat1 Inhibitor

US20260076937A1 · Seoul National University R&DB Foundation · Mar 19, 2026
A61K A61K
Application

Sustained Release Pharmaceutical Composition Of Sivelestat Or Salt Thereof And Preparation Method Thereof

US20260076936A1 · Beijing Tide Pharmaceutical Co., Ltd. · Mar 19, 2026
A61K A61K
Application

Prevention And Treatment Of Conditions Using Ethyl Pyruvate

US20260076935A1 · Mar 19, 2026
A61K A61K
Application

Methods For Reducing The Symptoms Of Neurodegenerative Disease In A Human

US20260076934A1 · David G Changaris · Mar 19, 2026
A61K A61K
Application

Collagen Production Promoter, Wrinkle Improver, Topical Skin Care Composition, And Beauty Food Or Beverage

US20260076933A1 · REFINE HOLDINGS CO., LTD. · Mar 19, 2026
A61K A23L
Application

Stable Levothyroxine Compositions In Aprotic Polar Solvents

US20260076932A1 · Xeris Pharmaceuticals, Inc. · Mar 19, 2026
A61K A61K
Application

L Dopa Microbiome Therapy

US20260076931A1 · Mar 19, 2026
A61K A61K
Application

Methods For Promoting Nerve Growth

US20260076930A1 · Mar 19, 2026
A61K A61K
Application

Treatment For Interstitial Lung Disease

US20260076929A1 · United Therapeutics Corporation · Mar 19, 2026
A61K A61K
Application

Treatment For Interstitial Lung Disease

US20260076928A1 · United Therapeutics Corporation · Mar 19, 2026
A61K A61K
Application

Palatable Compositions Including Sodium Phenylbutyrate And Uses Thereof

US20260076927A1 · Mar 19, 2026
A61K A61K
Application

Compounds For Use In Organ Preservation And Organ Transplantation

US20260076926A1 · ABREXA PHARMACEUTICALS, INC. · Mar 19, 2026
A61K A01N
Application

Epinephrine Formulations

US20260076925A1 · Mar 19, 2026
A61K A61K
Application

Compositions And Methods Of Treatment For Tinea Pedis

US20260076924A1 · Mar 19, 2026
A61K A61K
Application

Method And Composition To Reduce Or Inhibit Advanced Glycation End Products

US20260076923A1 · Mar 19, 2026
A61K A61K
Application

Decreasing Acinetobacter Populations In The Microbiome

US20260076922A1 · Mar 19, 2026
A61K A61K
Application

Transdermal Pharmaceutical Formulations For The Treatment Of Multiple Sclerosis

US20260076921A1 · Mar 19, 2026
A61K A61K
Application

Method For Robotic Assisted Heart Transplant

US20260076762A1 · KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE · Mar 19, 2026
A61B A61B
Application

Method And Device For Whole Organ Pulsed Electric Field Application For Irreversible Electroporation

US20260076734A1 · Mar 19, 2026
A61B A61K